News

GM-soy: A doubt  follows a yes
Enlarge image

Agri-biotechItalyGermanyEU

GM-soy: A doubt follows a yes

25.06.2012 - A European authority says Monsanto's roundup-ready soy is safe for man and environment. But there is doubt remaining.

Parma/Munich – For the first time, the European Food Safety Authority (EFSA) has approved the cultivation of genetically modified (GM) soy. So far, the  GM soy "roundup-ready" by US-industry leader Monsanto can only be imported to the EU. The Scientific Opinion published by the EFSA’s GMO panel now paves the way for EU Commissioner John Dalli. The Commission can give Monsanto the green light for cultivating the crop on European soils if the EU member states will not achieve a qualified majority on the issue.

However, there might be a fierce head wind blowing. German anti-GMO association Testbiotech e.V. points out that there's a legal minefield in the way. A study done on behalf of Testbiotech says that an expected admittance might violate EU law. Matter of concern: the EFSA opinion itself. According to the study, the EFSA should have also tested if the residues of pesticides to be used (in this case glyphosate) could have negative effects on human health. Not implementing this concern in the risk assessment could be equivalent to a breach of EU laws. The crop in question is soybean 40-3-2. It carries a gene that makes it tolerant to glyphosate (brand name: Roundup). That is why the soybean is also dubbed "roundup-ready soy". The EFSA opinion clearly regulates the use of this pesticide: "It should result in similar or reduced environmental impacts compared with conventional soybean cultivation." The panel also recommends that case-specific monitoring of (1) changes in weed community diversity; and (2) the evolution of resistance to glyphosate in weeds should be deployed.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.54 EUR103.6%

FLOP

  • THROMBOGENICS (B)8.51 EUR-52.2%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 11.07.2014